ClinicalTrials.gg
CompletedNCT03969992Updated Aug 7, 2025Results posted

A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact

A Phase 2 interventional study of AeroFact and nCPAP in Respiratory Distress Syndrome in Premature Infant, sponsored by Aerogen Pharma Limited. Completed at 41 sites in 2 countries. Open to participants aged 26 Weeks to 31 Weeks. Per ClinicalTrials.gov, last updated 2025-08-07.

Sponsored by Aerogen Pharma Limited · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
261
Allocation
Randomized
Ages
26 Weeks to 31 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 324 studies in Respiratory Distress Syndrome with a site in United States — 46 open to participants now, 56 under way, 7 of them phase 3. Respiratory Distress Syndrome · United States.

Enrollment
45th of 250
261 · median 52
Started
2020
with 62 others
Phase 2
74 of 324
8 open now
Registered
174th of 324
by date

Among the 324 studies in Respiratory Distress Syndrome with a site in United States, this one is the 45th largest by enrollment of the 250 interventional ones that give a count, is one of 63 that started in 2020, is one of 74 in phase 2, and was the 174th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

46 of the 324 studies in Respiratory Distress Syndrome with a site in United States are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 26 Weeks to 31 Weeks · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 324 studies in Respiratory Distress Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this two-part Phase 2 study is to assess the safety, tolerability and efficacy of aerosolized SF-RI 1 (AeroFact) when delivered via nCPAP at two different doses.

Read the detailed description

Part I Primary Objective To determine an optimal dose of AeroFact administered by nasal continuous positive airway pressure (nCPAP) versus stand of care in reducing the rate of intubation/cannulation and bolus surfactant instillation in the first 7 days after birth.

Part II Primary Objective To evaluate pulmonary outcomes and respiratory utilization at 3, 6, 9, and 12 months post-menstrual age (PMA)

03

Conditions studied

  • Respiratory Distress Syndrome in Premature Infant

Keywords

  • Respiratory Distress Syndrome
  • BPD
  • surfactant
  • Preterm Infant
04

Who can participate

Ages eligible
26 Weeks to 31 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Parental consent obtained prior to study procedures being performed (pre-natal consent is allowed)
  2. 26 0/7 to 30 6/7 weeks of gestational age
  3. Weight \<2.0 Kg
  4. Respiratory Severity Score (RSS) 1.4-2.0

Exclusion criteria

Exclusion Criteria:

  1. Apgar score less than or equal to 5 at five minutes after birth
  2. Need for chest compressions or administration of epinephrine or bicarbonate in the delivery room
  3. Premature rupture of membranes (PROM) > 14 days
  4. Need for intubation and/or mechanical ventilation prior to enrollment
  5. Active pneumothorax requiring chest tube
  6. Significant congenital anomaly, chromosomal abnormality
  7. Concomitant treatments with inhaled nitric oxide
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
261 participants (actual)

Study arms

  • Other
    nCPAP alone

    Standard of Care (nasal continuous positive airway pressure-nCPAP) with instilled bolus surfactant when medically necessary

    Other: nCPAP

  • Experimental
    Drug: Low Dose AeroFact

    AeroFact-low dose SF-RI 1

    Drug: AeroFact

  • Experimental
    Drug: High Dose AeroFact

    AeroFact-high dose SF-RI 1

    Drug: AeroFact

Interventions

  • DrugAeroFact

    Aerosolized SF-RI 1

    Also known as: SF-RI 1

  • OthernCPAP

    nCPAP (nasal continuous positive airway pressure) alone

06

What researchers measure

Primary outcomes

  1. Intubation/Cannulation and Instilled Surfactant

    Number of patients who require intubation/cannulation with bolus surfactant instillation

    Time frame: First 7 days of life

Secondary outcomes

  1. Time to First Intubation/Cannulation and Bolus Surfactant Instillation

    Time from randomization to intubation/cannulation and bolus surfactant instillation in the first 7 days of life

    Time frame: First 7 days of life

  2. Proportion of Infants Who Received Multiple Doses of Bolus Surfactant

    Time frame: First 7 days of life

  3. Number of Days on Invasive Mechanical Ventilation

    Total number of days each participant required support with invasive mechanical ventilation

    Time frame: Assessed daily from birth to 40 weeks post-menstrual age or discharge

  4. Proportion of Patients Survived Without Bronchopulmonary Dysplasia (BPD) at 36 Weeks Post-menstrual Age (PMA)

    Total number of patients per treatment group who were alive and did not experience BPD at 36 weeks PMA

    Time frame: Birth to 36 weeks post-menstrual age

  5. Proportion of Patients Survived Without Bronchopulmonary Dysplasia (BPD) at 40 Weeks Post-menstrual Age (PMA)

    Total number of patients per treatment group who were alive and did not experience BPD at 40 weeks PMA

    Time frame: Birth to 40 weeks post-menstrual age

07

Results

Posted Aug 7, 2025

Participant flow

Part 1: Birth to Discharge/40 Weeks PMA
Participant flow — Part 1: Birth to Discharge/40 Weeks PMA
MilestoneControl: nCPAP AloneDrug: Low Dose AeroFactDrug: High Dose AeroFact
Started928386
Completed898081
Not completed335
Withdrew: Withdrawal by subject103
Withdrew: Death232
Part 2: Discharge/40 Wks PMA to 12 Mos
Participant flow — Part 2: Discharge/40 Wks PMA to 12 Mos
MilestoneControl: nCPAP AloneDrug: Low Dose AeroFactDrug: High Dose AeroFact
Started898081
Completed747171
Not completed15910
Withdrew: Lost to follow-up1289
Withdrew: Physician decision001
Withdrew: Withdrawal by subject310

Outcome measures

PrimaryIntubation/Cannulation and Instilled Surfactant

Number of patients who require intubation/cannulation with bolus surfactant instillation

Time frame:
First 7 days of life
Reported as:
Count of participants · Participants
Intubation/Cannulation and Instilled Surfactant
ParticipantsControl: nCPAP AloneDrug: Low Dose AeroFactDrug: High Dose AeroFact
Intubation/Cannulation and Instilled Surfactant452126
Statistical analysis
  • Control: nCPAP Alone vs Drug: Low Dose AeroFact vs Drug: High Dose AeroFact · Generalized estimating equation method · p = 0.1924 (A closed test procedure is used to protect the type I error rate; the order of testing was: AeroFact high dose compared to control and if significant (p-value \<0.05), the AeroFact low dose was compared to the control.)
SecondaryTime to First Intubation/Cannulation and Bolus Surfactant Instillation

Time from randomization to intubation/cannulation and bolus surfactant instillation in the first 7 days of life

Time frame:
First 7 days of life
Reported as:
Median · hours
Time to First Intubation/Cannulation and Bolus Surfactant Instillation
hoursControl: nCPAP AloneDrug: Low Dose AeroFactDrug: High Dose AeroFact
Time to First Intubation/Cannulation and Bolus Surfactant Instillation17.5 (2.0 to 53.9)13.6 (3.2 to 43.4)22.4 (1.8 to 53.7)
SecondaryProportion of Infants Who Received Multiple Doses of Bolus Surfactant
Time frame:
First 7 days of life
Reported as:
Count of participants · Participants
Proportion of Infants Who Received Multiple Doses of Bolus Surfactant
ParticipantsControl: nCPAP AloneDrug: Low Dose AeroFactDrug: High Dose AeroFact
Proportion of Infants Who Received Multiple Doses of Bolus Surfactant715
SecondaryNumber of Days on Invasive Mechanical Ventilation

Total number of days each participant required support with invasive mechanical ventilation

Time frame:
Assessed daily from birth to 40 weeks post-menstrual age or discharge
Reported as:
Mean · Days
Number of Days on Invasive Mechanical Ventilation
DaysControl: nCPAP AloneDrug: Low Dose AeroFactDrug: High Dose AeroFact
Number of Days on Invasive Mechanical Ventilation4.8 ± 7.16.0 ± 16.74.0 ± 4.7
SecondaryProportion of Patients Survived Without Bronchopulmonary Dysplasia (BPD) at 36 Weeks Post-menstrual Age (PMA)

Total number of patients per treatment group who were alive and did not experience BPD at 36 weeks PMA

Time frame:
Birth to 36 weeks post-menstrual age
Reported as:
Count of participants · Participants
Proportion of Patients Survived Without Bronchopulmonary Dysplasia (BPD) at 36 Weeks Post-menstrual Age (PMA)
ParticipantsControl: nCPAP AloneDrug: Low Dose AeroFactDrug: High Dose AeroFact
Proportion of Patients Survived Without Bronchopulmonary Dysplasia (BPD) at 36 Weeks Post-menstrual Age (PMA)695553
SecondaryProportion of Patients Survived Without Bronchopulmonary Dysplasia (BPD) at 40 Weeks Post-menstrual Age (PMA)

Total number of patients per treatment group who were alive and did not experience BPD at 40 weeks PMA

Time frame:
Birth to 40 weeks post-menstrual age
Reported as:
Count of participants · Participants
Proportion of Patients Survived Without Bronchopulmonary Dysplasia (BPD) at 40 Weeks Post-menstrual Age (PMA)
ParticipantsControl: nCPAP AloneDrug: Low Dose AeroFactDrug: High Dose AeroFact
Proportion of Patients Survived Without Bronchopulmonary Dysplasia (BPD) at 40 Weeks Post-menstrual Age (PMA)745856

Adverse events

Collected over AEs and SAEs were collected from randomization through NICU discharge or 40 weeks post-menstrual age (PMA) in Part 1. Only fatal SAEs were collected for up to 12 months in Part 2.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control: nCPAP Alone2/92 (2.2%)7/92 (7.6%)43/92 (46.7%)
Drug: Low Dose AeroFact3/83 (3.6%)9/83 (10.8%)45/83 (54.2%)
Drug: High Dose AeroFact2/86 (2.3%)5/86 (5.8%)42/86 (48.8%)
Most frequent serious events
Most frequent serious events
EventControl: nCPAP AloneDrug: Low Dose AeroFactDrug: High Dose AeroFact
Necrotizing enterocolitis neonatalGastrointestinal disorders2/922/832/86
Gastrointestinal perforationGastrointestinal disorders1/922/830/86
PneumothoraxRespiratory, thoracic and mediastinal disorders1/922/832/86
Pulmonary hemorrhage neonatalRespiratory, thoracic and mediastinal disorders0/922/830/86
Intraventricular hemorrhage neonatalNervous system disorders0/922/830/86
Cardiac dysfunctionCardiac disorders0/921/830/86
Acute kidney injuryRenal and urinary disorders0/921/830/86
SepsisInfections and infestations1/920/831/86
Meconium ileusGastrointestinal disorders1/920/830/86
Cardiac tamponadeCardiac disorders1/920/830/86
Most frequent other events
Showing 10 of 14
Most frequent other events
EventControl: nCPAP AloneDrug: Low Dose AeroFactDrug: High Dose AeroFact
Intraventricular hemorrhage neonatalNervous system disorders6/9215/8318/86
Retinopathy or prematurityEye disorders14/9213/8313/86
Patent ductus arteriosusCongenital, familial and genetic disorders11/925/834/86
Bradycardia neonatalCardiac disorders2/926/831/86
PneumothoraxRespiratory, thoracic and mediastinal disorders3/925/834/86
Necrotizing enterocolitis neonatalGastrointestinal disorders5/925/835/86
SepsisInfections and infestations4/925/833/86
Patent ductus arteriosus repairSurgical and medical procedures4/921/830/86
Gastrointestinal perforationGastrointestinal disorders1/923/830/86
Infantile apneaRespiratory, thoracic and mediastinal disorders3/921/831/86

Baseline characteristics

All randomized patients were included in the ITT and Safety analysis populations, regardless of whether or not they received study treatment.

Age, Continuous
Age, Continuous(weeks gestational age)Control: nCPAP AloneDrug: Low Dose AeroFactDrug: High Dose AeroFactTotal
Mean29.2 ± 1.329.1 ± 1.429.1 ± 1.529.2 ± 1.4
Sex: Female, Male
Sex: Female, Male(Participants)Control: nCPAP AloneDrug: Low Dose AeroFactDrug: High Dose AeroFactTotal
Female473837122
Male454549139
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Control: nCPAP AloneDrug: Low Dose AeroFactDrug: High Dose AeroFactTotal
Hispanic or Latino13221247
Not Hispanic or Latino775872207
Unknown or Not Reported2327
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Control: nCPAP AloneDrug: Low Dose AeroFactDrug: High Dose AeroFactTotal
American Indian or Alaska Native0011
Asian31610
Native Hawaiian or Other Pacific Islander0000
Black or African American16121543
White575048155
More than one race0022
Unknown or Not Reported16201450
Birth weight
Birth weight(grams)Control: nCPAP AloneDrug: Low Dose AeroFactDrug: High Dose AeroFactTotal
Mean1195.1 ± 297.91245.1 ± 301.51248.7 ± 303.91228.7 ± 300.9
Vaginal delivery
Vaginal delivery(Participants)Control: nCPAP AloneDrug: Low Dose AeroFactDrug: High Dose AeroFactTotal
Count of participants14251958
Multiple gestation
Multiple gestation(Participants)Control: nCPAP AloneDrug: Low Dose AeroFactDrug: High Dose AeroFactTotal
Count of participants30292685
Age at Randomization
Age at Randomization(hours)Control: nCPAP AloneDrug: Low Dose AeroFactDrug: High Dose AeroFactTotal
Mean10.0 ± 7.28.2 ± 6.58.9 ± 6.99.1 ± 6.9

2 further baseline measures are reported on the registry.

08

Study locations

41 sites
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • Alta Bates Summit
    Berkeley, California 94705, United States
  • Children's Hospital Orange County
    Orange, California 92868, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • University of Florida Health
    Jacksonville, Florida 32209, United States
  • Wolfson Children's Hospital
    Jacksonville, Florida 32209, United States
  • South Miami Hospital
    Miami, Florida 33146, United States
  • Advent Health
    Orlando, Florida 32803, United States
  • Winnie Palmer Hospital
    Orlando, Florida 32806, United States
  • Northside Hospital Atlanta
    Atlanta, Georgia 30042, United States
  • University of Illinois
    Chicago, Illinois 60612, United States
  • Hospital of South Bend
    South Bend, Indiana 46601, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Barbara Bush Medical Center
    Portland, Maine 04102, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Holy Cross Hospital
    Silver Spring, Maryland 20910, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Children's and Women's (C & W) Mott Hospital
    Ann Arbor, Michigan 48109, United States
  • Children's Health Care d/b/a Children's Minnesota
    Minneapolis, Minnesota 55404, United States
  • University of Minnesota Masonic Children's Hospital
    Minneapolis, Minnesota 55454, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • University of Mississippi
    Jackson, Mississippi 39216, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Maimonides Hospital
    Brooklyn, New York 11219, United States
  • Mount Sinai Kravis Children's Hospital
    New York, New York 10029, United States
  • Columbia University Medical Center/New York Presbyterian Hospital
    New York, New York 10032, United States
  • NY Presbyterian Morgan Stanley Children's Hospital-Columbia
    New York, New York 10032, United States
  • West Chester Medical Center-Maria Fareri Children's Hospital
    Valhalla, New York 10595, United States
  • Levine Children's Hospital
    Charlotte, North Carolina 28203, United States
  • Grant Hospital
    Columbus, Ohio 43205, United States
  • Texas Health-Methodist Harris
    Fort Worth, Texas 76104, United States
  • Women's Hospital of Texas
    Houston, Texas 77054, United States
  • Children's Hospital of San Antonio (CHofSA)
    San Antonio, Texas 78207, United States
  • Methodist Children's Hospital
    San Antonio, Texas 78229, United States
  • North Central Baptist Hospital
    San Antonio, Texas 78258, United States
  • University of Virginia
    Charlottesville, Virginia 22947, United States
  • University of Washington
    Seattle, Washington 98195, United States
  • IWK Hospital
    Halifax, Nova Scotia, Canada
  • The Ottawa Hospital
    Ottawa, Ontario, Canada
  • Mt. Sinai Hospital
    Toronto, Ontario, Canada
  • CHU de Québec-Université Laval
    Québec, Quebec, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Aug 2023, 41 months.

Results were first posted in Aug 2025, 2 years after primary completion.

Of 59 phase 2 interventional studies under Respiratory Distress Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's 41 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2019
First posted
May 31, 2019
StartActual
Mar 4, 2020
Primary completionActual
Aug 4, 2023
CompletionActual
Aug 5, 2024
Results first posted
Aug 7, 2025
Last update
Aug 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03969992
Lead sponsor
Aerogen Pharma Limited
Responsible party
Sponsor
First posted
May 31, 2019
Start date
Mar 4, 2020
Primary completion
Aug 4, 2023
Completion
Aug 5, 2024
Results posted
Aug 7, 2025
Last update
Aug 7, 2025

Study contacts

David Durand, MD
study director · Aerogen Pharma Corp

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion